2-47799402-GGT-GGTGT
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.1421_1422dupTG(p.Gln475CysfsTer7) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,613,990 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152136Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251168Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135744
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461854Hom.: 0 Cov.: 34 AF XY: 0.00000138 AC XY: 1AN XY: 727222
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152136Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74314
ClinVar
Submissions by phenotype
Lynch syndrome 5 Pathogenic:2
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
- -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant inserts 2 nucleotides in exon 4 of the MSH6 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with Lynch syndrome or suspected Lynch syndrome (PMID: 15483016, 15217520, 18301448, 21039432, 25430799, 27273229, 31822864), breast/ovarian cancer (PMID: 23612316, 27153395, 27616075). This variant has been identified in 1/251168 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The c.1421_1422dupTG pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a duplication of TG at nucleotide position 1421, causing a translational frameshift with a predicted alternate stop codon (p.Q475Cfs*7). This mutation has been reported in multiple individuals with Lynch syndrome (Plaschke J et al. Int. J. Cancer. 2002 Feb;97:643-8; Steinke V et al. Eur. J. Hum. Genet. 2008 May;16:587-92; Kunstmann E et al. BMC Med. Genet. 2004 Jun;5:16; Moline J et al. Gynecol. Oncol. 2013 Jul;130:121-6). Additionally, this mutation has been reported in trans with another pathogenic MSH6 mutation in a sibling pair with constitutional mismatch repair-deficiency (CMMR-D) syndrome (Jasperson KW et al. Clin Genet. 2011;80:394–397). Of note, this alteration is also designated as nt1510insTG and c.1422_1423insTG in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Lynch syndrome Pathogenic:1
Coding sequence variation resulting in a stop codon -
not provided Pathogenic:1
The MSH6 c.1421_1422dup (p.Gln475Cysfs*7) variant alters the translational reading frame of the MSH6 mRNA and causes the premature termination of MSH6 protein synthesis. In the published literature, this variant has been reported in multiple individuals and families with Lynch syndrome-associated cancers in the published literature (PMIDs: 28944238 (2017), 27616075 (2016), 25430799 (2015), 18301448 (2008), 15483016 (2004), 11807791 (2002)). In addition, it has been reported in trans with another MSH6 variant in siblings with constitutional mismatch repair deficiency syndrome (PMID: 21039432 (2011)). Based on the available information, this variant is classified as pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln475Cysfs*7) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is present in population databases (rs63750854, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with rectal cancer, breast cancer, adenomatous polyps, and cafe au lait macules (PMID: 11807791, 15483016, 21039432, 27616075). Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this MSH6 variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 1,370,736 individuals referred to our laboratory for MSH6 testing. This variant is also known as 1510insTG. ClinVar contains an entry for this variant (Variation ID: 89193). For these reasons, this variant has been classified as Pathogenic. -
Endometrial carcinoma Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at